GB2407499B - Vitamin D3 analogue for use in the treatment of BPH - Google Patents

Vitamin D3 analogue for use in the treatment of BPH

Info

Publication number
GB2407499B
GB2407499B GB0325598A GB0325598A GB2407499B GB 2407499 B GB2407499 B GB 2407499B GB 0325598 A GB0325598 A GB 0325598A GB 0325598 A GB0325598 A GB 0325598A GB 2407499 B GB2407499 B GB 2407499B
Authority
GB
United Kingdom
Prior art keywords
bph
analogue
vitamin
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
GB0325598A
Other versions
GB0325598D0 (en
GB2407499A (en
Inventor
Luciano Adorini
Enrico Colli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioxell SpA
Original Assignee
Bioxell SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioxell SpA filed Critical Bioxell SpA
Priority to GB0325598A priority Critical patent/GB2407499B/en
Publication of GB0325598D0 publication Critical patent/GB0325598D0/en
Priority to CA002476224A priority patent/CA2476224A1/en
Priority to PT103177A priority patent/PT103177A/en
Priority to SG200404316A priority patent/SG110107A1/en
Priority to AU2004203436A priority patent/AU2004203436A1/en
Priority to US10/903,211 priority patent/US7332482B2/en
Priority to CH01553/04A priority patent/CH698144B1/en
Priority to BR0404050-3A priority patent/BRPI0404050A/en
Priority to NZ535531A priority patent/NZ535531A/en
Priority to EA200401100A priority patent/EA010240B1/en
Priority to FR0410073A priority patent/FR2859910B1/en
Priority to CA002540325A priority patent/CA2540325A1/en
Priority to US10/573,164 priority patent/US20070054887A1/en
Priority to EP04765598A priority patent/EP1673096A1/en
Priority to NL1027109A priority patent/NL1027109C2/en
Priority to EP04789064A priority patent/EP1663250A4/en
Priority to AU2004275845A priority patent/AU2004275845A1/en
Priority to BRPI0414701-4A priority patent/BRPI0414701A/en
Priority to JP2006527365A priority patent/JP2007506699A/en
Priority to BE2004/0472A priority patent/BE1016292A3/en
Priority to CNB2004100800817A priority patent/CN100488511C/en
Priority to PCT/EP2004/010760 priority patent/WO2005027923A1/en
Priority to JP2006528270A priority patent/JP2007506780A/en
Priority to PCT/US2004/031532 priority patent/WO2005030223A1/en
Publication of GB2407499A publication Critical patent/GB2407499A/en
Priority to HK05108113.0A priority patent/HK1085373A1/en
Priority to IL174369A priority patent/IL174369A0/en
Priority to US11/977,502 priority patent/US20080207769A1/en
Application granted granted Critical
Publication of GB2407499B publication Critical patent/GB2407499B/en
Priority to AU2008203397A priority patent/AU2008203397A1/en
Priority to JP2008209429A priority patent/JP2009035559A/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
GB0325598A 2003-09-24 2003-11-03 Vitamin D3 analogue for use in the treatment of BPH Expired - Fee Related GB2407499B (en)

Priority Applications (29)

Application Number Priority Date Filing Date Title
GB0325598A GB2407499B (en) 2003-11-03 2003-11-03 Vitamin D3 analogue for use in the treatment of BPH
AU2004203436A AU2004203436A1 (en) 2003-09-24 2004-07-29 Compound and use in treatment
PT103177A PT103177A (en) 2003-09-24 2004-07-29 1-ALPHA-FLUORO-25-HYDROXY-16,23E-DIENE-26,27-BIS-HOMO-20-EPI-COLECALCIFEROL, ITS SALTS OR ESTERS AND ITS USE IN THE MANUFACTURE OF MEDICINES
SG200404316A SG110107A1 (en) 2003-09-24 2004-07-29 Compound and use in treatment
CA002476224A CA2476224A1 (en) 2003-09-24 2004-07-29 Compound and use in treatment
US10/903,211 US7332482B2 (en) 2003-09-24 2004-07-29 Method for treating benign prostatic hyperplasia
CH01553/04A CH698144B1 (en) 2003-09-24 2004-09-22 Analogue of vitamin D3
BR0404050-3A BRPI0404050A (en) 2003-09-24 2004-09-22 Use of a compound or pharmaceutically acceptable salt or ester thereof, pharmaceutical formulation, packaged formulation, compound, and method for preventing and / or treating benign prostate hyperplasia in patients in need of such prevention or treatment.
NZ535531A NZ535531A (en) 2003-09-24 2004-09-23 Compound and use in treatment
EA200401100A EA010240B1 (en) 2003-09-24 2004-09-23 1-alpha-fluoro-25-hydroxy-16,23e-diene-26,27-bishomo-20-epicholecalciferol and use for treatment thereof
FR0410073A FR2859910B1 (en) 2003-09-24 2004-09-23 USE OF 1-ALPHA-FLUORO-25-HYDROXY-16,23E-DIENE-26,27-BISHOMO-20-EPI-CHOLECALCIFEROL FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA
AU2004275845A AU2004275845A1 (en) 2003-09-24 2004-09-24 Methods for treating bladder dysfunction
JP2006528270A JP2007506780A (en) 2003-09-24 2004-09-24 Method for treating bladder dysfunction
EP04765598A EP1673096A1 (en) 2003-09-24 2004-09-24 Use of a vitamin d3 analogue for the treatment of benign prostatic hyperplasia
NL1027109A NL1027109C2 (en) 2003-09-24 2004-09-24 Connection and use with treatment.
EP04789064A EP1663250A4 (en) 2003-09-24 2004-09-24 Methods for treating bladder dysfunction
CA002540325A CA2540325A1 (en) 2003-09-24 2004-09-24 Methods for treating bladder dysfunction
BRPI0414701-4A BRPI0414701A (en) 2003-09-24 2004-09-24 use of a vitamin d compound, method of prevention or treatment of bladder dysfunction in a patient, vitamin d compound e, kit
JP2006527365A JP2007506699A (en) 2003-09-24 2004-09-24 Use of vitamin D3 analogs for the treatment of benign prostatic hyperplasia
BE2004/0472A BE1016292A3 (en) 2003-09-24 2004-09-24 CONNECTION AND USE IN TREATMENT.
CNB2004100800817A CN100488511C (en) 2003-09-24 2004-09-24 Compound and use for preparation of the medicament for treatment of benign prostatic hyperplasia and relative diseases
PCT/EP2004/010760 WO2005027923A1 (en) 2003-09-24 2004-09-24 Use of vitamin d3 analogue for the treatment of benign prostatic hyperplasia
US10/573,164 US20070054887A1 (en) 2003-09-24 2004-09-24 Methods for treating bladder dysfunction
PCT/US2004/031532 WO2005030223A1 (en) 2003-09-24 2004-09-24 Methods for treating bladder dysfunction
HK05108113.0A HK1085373A1 (en) 2003-09-24 2005-09-16 Compound and use in the manufacture of a medicament for the treatment of benign prostatic hyperplasia and associated symptoms
IL174369A IL174369A0 (en) 2003-09-24 2006-03-16 Methods for treating bladder dysfunction
US11/977,502 US20080207769A1 (en) 2003-09-24 2007-10-24 Method for treating benign prostatic hyperplasia
AU2008203397A AU2008203397A1 (en) 2003-09-24 2008-07-30 Compound and use in treatment
JP2008209429A JP2009035559A (en) 2003-09-24 2008-08-18 Use of vitamin d3 analog for the treatment of benign prostatic hyperplasia

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0325598A GB2407499B (en) 2003-11-03 2003-11-03 Vitamin D3 analogue for use in the treatment of BPH

Publications (3)

Publication Number Publication Date
GB0325598D0 GB0325598D0 (en) 2003-12-10
GB2407499A GB2407499A (en) 2005-05-04
GB2407499B true GB2407499B (en) 2008-02-27

Family

ID=29725834

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0325598A Expired - Fee Related GB2407499B (en) 2003-09-24 2003-11-03 Vitamin D3 analogue for use in the treatment of BPH

Country Status (1)

Country Link
GB (1) GB2407499B (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0808833A2 (en) * 1996-05-23 1997-11-26 F. Hoffmann-La Roche Ag Vitamin D3 analogs
US6030963A (en) * 1995-11-22 2000-02-29 Hoffmann-La Roche Inc. 16-ene-26,27-bishomo cholecalciferols
US6331642B1 (en) * 1999-07-12 2001-12-18 Hoffmann-La Roche Inc. Vitamin D3 analogs

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6030963A (en) * 1995-11-22 2000-02-29 Hoffmann-La Roche Inc. 16-ene-26,27-bishomo cholecalciferols
EP0808833A2 (en) * 1996-05-23 1997-11-26 F. Hoffmann-La Roche Ag Vitamin D3 analogs
US6331642B1 (en) * 1999-07-12 2001-12-18 Hoffmann-La Roche Inc. Vitamin D3 analogs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
M. Brandt et al, J.Pharm.Sci., (2003), 92(10), 1981-1989 *

Also Published As

Publication number Publication date
GB0325598D0 (en) 2003-12-10
GB2407499A (en) 2005-05-04

Similar Documents

Publication Publication Date Title
WO2006015263A3 (en) Lonidamine analogs
IL175529A0 (en) Methods and compositions for the treatment of metabolic disorders
EP1727530A4 (en) Topical formulations for the treatment of skin conditions
ZA200607433B (en) Methods and compositions for the treatment of gastroin-testinal disorders
IL178012A0 (en) Diphenyl-indol-2-on compounds and their use in the treatment of cancer
GB0520687D0 (en) Skin treatment formulations
AU2003286567A8 (en) Methods for the treatment of skin disorders
IL178980A0 (en) Sulfonylethyl phosphorodiamidates for use in the treatment of cancer
HK1075844A1 (en) Formulation and methods for the treatment of thrombocythemia
AU2003212634A8 (en) Compounds useful in the treatment of cancer
LT2340872T (en) New pharmaceutical formulations useful in the treatment of insomnia
ZA200705881B (en) Formulations and treatments for well-being
EG24959A (en) Indoles useful in the treatment of androgenreceptor related diseases.
EP1562606A4 (en) Methods of using vitamin d compounds in the treatment of myelodysplastic syndromes
IL166062A0 (en) Compositions and methods for therapeutic treatment
GB2407499B (en) Vitamin D3 analogue for use in the treatment of BPH
GB0425633D0 (en) Topical formulations for use in the treatment or prevention of dermatological conditions
EP1684795A4 (en) Methods and agents for the treatment of cancer
GB0201025D0 (en) The treatment of degenerative diseases
EP1648469A4 (en) Antiglucocorticoids for the treatment of catatonia
GB0427637D0 (en) Topical formulations for use in the treatment or prevention of skin cancers
IL175774A0 (en) Use of siramesine in the treatment of cancer
GB0317500D0 (en) Treatment of bph
GB0310147D0 (en) A composition for use in the treatment of a skin condition in a subject
AU2003247094A8 (en) Enhancing the effect of radioimmunotherapy in the treatment of tumors

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20091103